Stay updated with breaking news from Rexafemme. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Scynexis said no adverse events or contamination problems have been reported for Brexafemme, an antifungal approved for treating vaginal yeast infections. The biotech said the risk of cross-contamination stems from the processes of the small molecule’s third-party manufacturer. ....
Scynexis Inc. shares were up 60% to $2.67 after the company said it has entered into an exclusive licence agreement for Brexafemme ibrexafungerp tablets with GSK Plc.
Brexafemme complements GSK’s industry-leading infectious disease portfolio with an FDA approved treatment for vulvovaginal candidiasisSCYNEXIS will receive an upfront payment of $90 million with. | March 30, 2023 ....
GSK is set to gain exclusive rights to first-in-class oral antifungal Brexafemme for vulvovaginal candidiasis from SCYNEXIS. The exclusive licence agreement will enable GSK to commercialise. | March 30, 2023 ....